Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma
In this case, we describe the potential risk of developing an infectious complication leading to a secondary malignancy after a short course of immunotherapy. We report a patient who presented with Epstein–Barr virus (EBV) driven Hodgkin’s lymphoma after treatment with a short course of daratumumab...
Saved in:
Main Authors: | Moeen Mohammadi-Oroujeh, Ansa Mehreen, David L. Grinblatt |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2023/6669174 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01) -
Complete Remission of Methotrexate-Related Epstein-Barr-Virus-Associated Hodgkin-Like Lymphoma following Withdrawal of MTX Coupled with Clarithromycin Administration
by: Nobuo Takemori, et al.
Published: (2012-01-01) -
Concurrent Presentation of Hodgkin Lymphoma and Multiple Myeloma
by: Rekha Chandran, et al.
Published: (2013-01-01) -
Primary Intraocular Lymphoma in a Patient with Bilateral Epstein-Barr Virus Panuveitis
by: Seyedeh Maryam Hosseini, et al.
Published: (2021-01-01) -
Variant Guillain-Barré Syndrome in a Patient with Non-Hodgkin’s Lymphoma
by: R. H. Bishay, et al.
Published: (2015-01-01)